Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-1821 in Healthy Adult Volunteers and in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD), including an open-label patient cohort.

Next Previous
Search
Trial Profile

A Phase 1 Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-1821 in Healthy Adult Volunteers and in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD), including an open-label patient cohort.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Losmapimod (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions
  • Acronyms CHDR1846
  • Sponsors Fulcrum Therapeutics

    • Most Recent Events

    • 30 Apr 2021 According to results published in the British Journal of Clinical Pharmacology, Geert Jan Groenveld is a principal investigator of this study
    • 30 Apr 2021 Results published in the British Journal of Clinical Pharmacology
    • 01 May 2020 Results assessing safety, tolerability, pharmacokinetics (PK), and target engagement (TE) of losmapimod in healthy volunteers (HV) and FSHD1 patients, presented at the 72nd Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top